Jaguar Health Highlights Promising Crofelemer Study Results

The latest update is out from Jaguar Animal Health ( (JAGX) ).

On May 9, 2025, Jaguar Health released a slide presentation detailing its ongoing efforts to develop and commercialize crofelemer for various indications, including HIV-related diarrhea and short bowel syndrome. Recent studies presented in April 2025 showed promising results for crofelemer in reducing parenteral support in patients with intestinal failure, potentially improving their quality of life. The company is also pursuing additional business development deals and regulatory designations to enhance its market positioning.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.

Jaguar Animal Health’s stock score is low due to substantial financial difficulties, characterized by high leverage, negative profitability, and bearish technical indicators. While there is some optimism from earnings calls and corporate events, persistent financial instability and clinical trial challenges weigh heavily on the stock’s potential.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of novel plant-based medicines to treat gastrointestinal disorders. Their primary products include Mytesi, an FDA-approved drug for noninfectious diarrhea in adults with HIV/AIDS, and Canalevia-CA1, conditionally approved for chemotherapy-induced diarrhea in dogs. The company is also working on expanding its product portfolio and market reach, particularly in Europe.

Average Trading Volume: 105,515

Technical Sentiment Signal: Sell

Current Market Cap: $7.41M

See more data about JAGX stock on TipRanks’ Stock Analysis page.